Ipilimumab as prostate cancer treatment
xsmb kết quả xổ số miền bắc hôm nayAlthough metastatic castration-resistant prostate cancer (mCRPC) typically has limited response to immunotherapy, a subset of patients with pretreatment evidence of active T cell responses in their tumors experienced prolonged survival following treatment with ipilimumab in a Phase II trial at MD Anderson.